FONT-SIZE Plus   Neg

EU Approves Roche's Perjeta To Treat Metastatic Breast Cancer

Roche announced that it has received approval from European regulators for its perjeta drug to help treat breast cancer.

The approval comes from the European Medicines Agency and covers patients with previously untreated HER2-positive metastatic breast cancer. The drug is approved in combination with two other treatments - Herceptin and docetaxel - in adult patients who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

The European approval comes after a late-stage trial showed that the combination of perjeta, Herceptin and chemotherapy provided patients with a median of 6.1 months longer without their disease worsening. It also provided a 34 percent reduction in the risk of death compared to Herceptin and chemotherapy alone.

The company said that perjeta is now approved in the EU, the U.S., and Switzerland for the treatment of people with this form of breast cancer. Further country approvals are anticipated during 2013.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Flying is the passion for British aviatrix Tracey Curtis Taylor, and she is now on a solo flight to cross three continents and 23 countries in her own vintage open cockpit biplane. She has already crossed half of her journey from U.K. to Australia with a target to cover 13 thousand miles. Sony Computer Entertainment Inc. Wednesday revealed that its popular PlayStation4 computer entertainment system has achieved total sales of more than 30.2 million units worldwide in a period of two years. The PS4 system is currently available in 124 countries. Cement giant LafargeHolcim (HCMLY.PK, HCMLF.PK), formed by the combination of French Lafarge and Swiss peer Holcim, Wednesday said its sales declined for the third quarter as well as nine months.
comments powered by Disqus
Follow RTT